Learning Objectives:

• Understand how Rheumatoid Arthritis is diagnosed and differentiated for Osteoarthritis. Recognizing Rheumatoid Arthritis as a true systemic disease.
• Become aware of the extraarticular manifestations of Rheumatoid Arthritis.
• Becomes familiar with commonly used DMARDs and Biologic drugs available to treat RA.

John Prior, DO, FACOI (he/him/his), Nephrologist, NEPA Nephrology Associates

Learning Objectives:

• Distinguish the clinical, synovial fluid, and polarized microscopy features of gout (MSU), pseudogout (CPPD), and BCP deposition disease, and apply these distinctions to guide appropriate diagnostic workup and initial management.
• Apply Urate-Lowering Therapy Principles Identify evidence-based indications for urate-lowering therapy (ULT), select appropriate first- and second-line agents based on patient comorbidities (including CKD, cardiovascular disease, and pharmacogenomics such as HLA-B*5801 status), and implement a treat-to-target strategy with concurrent flare prophylaxis.
• Enumerate the extra-articular manifestations of gout (renal, cardiovascular, metabolic) and CPPD (crowned dens syndrome, atypical OA), and explain why comprehensive management—including treatment of underlying metabolic disorders and cardiovascular risk reduction—is essential to improve patient outcomes beyond joint disease.

Rubaiya Mallay, DO, FACOI, FACR (she/her/hers), Rheumatologist, Suncoast Internal Medicine Consultants

Learning Objectives:

• Understand the unique clinical features of the spondyloarthropathies.
• Understand diagnostic criteria for SpA.
• Become familiar with current treatment options for this family of diseases.

Robert L. DiGiovanni, DO, MACOI, Rheumatology PD, Associate professor of Medicine, HCA Largo Hospital, Morsani College of Medicine

Learning Objectives:

• SSc Is a Multisystem Fibrotic Disease driven by the pathophysiologic triad of immune activation, vascular injury, and fibroblast activation — with ILD and PAH as the leading causes of mortality.
• Expanding Therapeutic Arsenal FDA-approved agents now include tocilizumab (IL-6 blockade), nintedanib (triple tyrosine kinase inhibitor), and nerandomilast (PDE4B inhibitor) — for Systemic Sclerosis
• Apply Myositis-Specific Antibody Profiles Correlate myositis-specific antibodies (Anti-TIF1γ, Anti-MDA-5, Anti-Jo-1, Anti-Mi-2) with their clinical phenotypes, prognostic implications, and malignancy associations to guide workup and management.

Rubaiya Mallay, DO, FACOI, FACR (she/her/hers), Rheumatologist, Suncoast Internal Medicine Consultants

Learning Objectives:

• Recall the clinical features and presentations of vasculitis in a case-based format.
• Interpretation of the unique labs used to help diagnose vasculitis.
• Become familiar with current treatment strategies for this group of disorders.

Robert L. DiGiovanni, DO, MACOI, Rheumatology PD, Associate professor of Medicine, HCA Largo Hospital, Morsani College of Medicine

Learning Objectives:

• HIV arthritis affects 12–63% of HIV patients on ART, highlighting its significant clinical burden.
• Understand rheumatic fever as an immunologically mediated late complication of Group A streptococcal (GAS) pharyngeal infection
• Prevention Is Key for Lyme disease. Proper tick removal within 36–48 hours, avoidance of folk remedies, and awareness of the VLA15 vaccine pipeline are all essential components of patient education.

Rubaiya Mallay, DO, FACOI, FACR (she/her/hers), Rheumatologist, Suncoast Internal Medicine Consultants

Learning Objectives:

• The learner should be familiar with the basic indications and approaches to arthrocentesis (non-ultrasound guided techniques)
• The learner should know the four basic categories of classification of synovial fluids
• Understand how synovial fluid analysis including compensated polarized light microscopy can aid in the diagnosis and correct treatment in patients with joint diseases.

Robert L. DiGiovanni, DO, MACOI, Rheumatology PD, Associate professor of Medicine, HCA Largo Hospital, Morsani College of Medicine

Learning Objectives:

• How to work up and diagnose a polyneuropathy.
• How to work up an acute neuropathy.
• How to recognize and diagnose a mononeuropathy multiplex.

Scott Spradlin, DO, FACP, FACOI, Vice President of Clinical Value and Innovation, Aetna

Learning Objectives:

• Diagnose selected genetic conditions.
• Anticipate selected conditions based upon patients’ genetics disorders.
• Correlate genetic inheritance with selected conditions.

Robert T. Hasty, DO, FACOI, FACP, Dean & Chief Academic Officer, Orlando College of Osteopathic Medicine (Proposed)

Learning Objectives:

• Diagnosis and management of myopathies and treatments.
• Diagnosis and management of Parkinson's, seizures, and motor disorders.
• Diagnosis and management of headaches and treatments.

Scott Spradlin, DO, FACP, FACOI, Vice President of Clinical Value and Innovation, Aetna

Learning Objectives:

• Educate patients on appropriate diets tailored to their comorbid conditions.
• Prevent exacerbations of selected conditions by prescribing appropriate diets.
• Improve patients’ health outcomes by choosing selected diets.

Robert T. Hasty, DO, FACOI, FACP, Dean & Chief Academic Officer, Orlando College of Osteopathic Medicine (Proposed)

Learning Objectives:

• Upon completion, participants will be able to describe and evaluate for common causes of telogen effluvium.
• Upon completion, participants will be able to describe the cutaneous manifestations of rheumatologic disease, namely dermatomyositis and lupus as well as identify the systemic comorbidities of psoriasis.
• Upon completion, participants will be able to identify common cutaneous manifestations of gastrointestinal, renal, endocrine, and hematologic diseases

Molly Menser, DO, Dermatologist/Clinical Preceptor, Kansas City University College of Osteopathic Medicine

Learning Objectives:

• Discuss clinical stratification for neurological cases.
• Discuss a general overview of multiple sclerosis.
• Discuss a general overview of types of strokes.

Scott Spradlin, DO, FACP, FACOI, Vice President of Clinical Value and Innovation, Aetna

Learning Objectives:

• Understand the changing ecosystem of Testosterone Replacement Therapy (TRT) Develop a framework/approach to evaluating Testosterone (T)
• Improve competence in management of low testosterone
• Apply skills and techniques to better serve your patients

Andrew J. Hamilton, DO (he/him/his), Family Medicine Residency Core Faculty, Henry Ford Genesys